Introduction
============

Papillary renal cell carcinoma (PRCC) is a complex malignant neoplasm and the second most frequent renal cell carcinoma (RCC) following renal clear cell carcinoma (CCRC), comprising \~18.5% of the total cases of RCC ([@b1-mmr-19-06-4685]). In 1997, Delahunt and Elbe ([@b2-mmr-19-06-4685]) described PRCC as comprising two subtypes, type 1 and type 2; however, Chevarie-Davis *et al* ([@b3-mmr-19-06-4685]) reported that the frequency of 'overlapping' PRCC, which possessed a certain overlapping features, was \~47%. Furthermore, the survival of patients with PRCC varies, particularly in cases of sporadic PRCC. Ha *et al* ([@b4-mmr-19-06-4685]) reported that the subclassification of PRCC did not affect the prognosis of patients with PRCC, whereas Tsimafeyeu *et al* ([@b5-mmr-19-06-4685]) demonstrated that the expression of fibroblast growth factor receptor 2 was a prognostic factor in the survival of patients with metastatic PRCC. At present, there is no effective treatment for patients with advanced PRCC ([@b6-mmr-19-06-4685]).

A number of genes have been previously identified to be frequently mutated in PRCC, including MET, SETD2, NF2, KDM6A, SMARCB1, FAT1, BAP1, PBRM1, STAG2, NFE2L2 and TP53 ([@b7-mmr-19-06-4685],[@b8-mmr-19-06-4685]). At present, the research conducted regarding PRCC-associated biomarkers is insufficient to meet clinical requirements for the diagnosis and prognosis of patients, and there remains a lack of knowledge regarding the use of PRCC-associated noncoding RNAs as biomarkers and their internal interactions. A previous study reported that the classification of different molecular subtypes may aid the prognosis of PRCC ([@b9-mmr-19-06-4685]). The requirement for improved understanding of the molecular mechanisms underlying the development and progression of PRCC is increasing. A recent study analyzed the expression of long noncoding RNAs (lncRNAs), which may serve as useful biomarkers for tumor staging, in PRCC using The Cancer Genome Atlas (TCGA) ([@b10-mmr-19-06-4685]). At present, there has been limited analysis of PRCC-associated competing endogenous RNA (ceRNA) networks involving lncRNAs in an entire genome.

The ceRNA hypothesis involves a complex post-transcriptional regulatory network in which lncRNAs, mRNAs and other RNAs act as natural microRNA (miRNA) sponges to suppress miRNA function by sharing one or more miRNA response elements ([@b11-mmr-19-06-4685]). At present, increasing evidence indicates that regulatory networks serve important roles in the occurrence, development and regulation of tumors, including breast, ovarian, kidney, colon and liver cancers ([@b12-mmr-19-06-4685]--[@b17-mmr-19-06-4685]).

To investigate the regulatory mechanisms of ceRNA networks in PRCC, and aid improvements in the diagnosis and prognosis of PRCC, a comprehensive analysis of the genomic and epigenomic landscape of PRCC was conducted to identify statistically significant genetic alterations in tumors in the present study. Following a series of analyses, an lncRNA-miRNA-mRNA ceRNA network was constructed and important genes were identified, which may aid the identification of the functions of noncoding RNAs in PRCC, and the associations between miRNA, lncRNA and mRNA. Reverse transcription-quantitative PCR (RT-qPCR) analysis revealed that the expression of a central lncRNA in the ceRNA network, lncRNA maternally expressed 3 (MEG3), was downregulated in PRCC tumor tissues compared with adjacent non-tumor tissues. Furthermore, Kaplan-Meier survival analyses identified 13 mRNAs, 15 lncRNAs and six miRNAs that significantly predicted the prognosis of patients with PRCC. The results of the present study provide a novel approach for the investigation of molecular mechanisms and prognostic biomarkers in PRCC.

Materials and methods
=====================

### Data source

mRNA and miRNA expression profiles and clinical characteristics of patients with PRCC were obtained from TCGA using the Data Transfer Tool ([cancergenome.nih.gov/](cancergenome.nih.gov/)), using the search terms 'Kidney', 'Kidney Renal Papillary Cell Carcinoma' and 'Transcriptome Profiling', resulting in 289 PRCC sample tissues and 32 non-tumor tissues. mRNA and miRNA sequence (seq) data are available open access, and the present research met the requirements of TCGA publishing guidelines. Following the acquisition of mRNA-seq and miRNA-seq data, lncRNA expression data were obtained by relocating probes in mRNA expression profiles to lncRNAs based on annotations from the GENCODE project (version 28; [gencodegenes.org/](gencodegenes.org/)) ([@b18-mmr-19-06-4685],[@b19-mmr-19-06-4685]).

### Identification and analysis of PRCC-associated mRNAs, lncRNAs and miRNAs

Differential expression analysis of mRNAs, lncRNAs and miRNAs was conducted using data from tumor and adjacent non-tumor tissues from patients with PRCC using edgeR, a Bioconductor package (version 3.6) in R software (version 3.5.0) ([@b20-mmr-19-06-4685]), with thresholds of \|log2-fold change\| ≥2.0 and adjusted P\<0.05; the false discovery rate (FDR) was adjusted using the Benjamini-Hochberg method ([@b21-mmr-19-06-4685]).

### Functional annotation of differentially expressed mRNAs (DEmRNAs) and construction of the protein-protein interaction (PPI) network

To determine the biological significance of DEmRNAs, Gene Ontology (GO) terms were assigned using the GO database ([geneontology.org/](geneontology.org/)) ([@b22-mmr-19-06-4685]) via the Database for Annotation Visualization and Integrated Discovery (DAVID; version 6.8; [david.ncifcrf.gov/](david.ncifcrf.gov/)) ([@b23-mmr-19-06-4685],[@b24-mmr-19-06-4685]). Additionally, Kyoto Encyclopedia of Genes and Genomes (KEGG) ([@b25-mmr-19-06-4685]--[@b27-mmr-19-06-4685]) pathway enrichment analysis of DEmRNAs was performed using KOBAS 3.0 (<http://kobas.cbi.pku.edu.cm/index.php>) ([@b28-mmr-19-06-4685]).

To further understand the protein-protein interactions between DEmRNAs, a PPI network was generated using the Search Tool for the Retrieval of Interacting Genes (version 10.5; [string-db.org/](string-db.org/)) database ([@b29-mmr-19-06-4685],[@b30-mmr-19-06-4685]). PPI networks were visualized using Cytoscape version 3.6.1 software ([@b31-mmr-19-06-4685]). Furthermore, the CytoHubba (Version 0.1) plug-in for Cytoscape ([@b32-mmr-19-06-4685]) was used to identify hub genes by ranking the participation degree in PPI networks.

### Construction of the ceRNA network

DElncRNAs were compared using the miRcode database (version 11; [mircode.org/](mircode.org/)) ([@b33-mmr-19-06-4685]), then miRNAs in selected pairs were compared with previously identified DEmiRNAs to obtain the final integrated lncRNA-miRNA pairs. Prediction of target genes for selected lncRNA-miRNA pairs of miRNAs was performed using three databases, miRTarBase (version 7.0) ([@b34-mmr-19-06-4685]), miRanda (version 3.3a) ([@b35-mmr-19-06-4685]), and TargetScan (version 7.1) ([@b36-mmr-19-06-4685]). Candidate target mRNAs were included in the three databases and intersected with previously identified DEmRNAs. Then, the lncRNA-miRNA-mRNA ceRNA network was reconstructed by assembling DElncRNA-DEmiRNA-DEmRNA associations visualized using Cytoscape (version 3.6.1). The sub-network of the ceRNA network was extracted using the Cytoscape plug-in MCODE (version 1.5.1) ([@b37-mmr-19-06-4685]).

### RNA extraction and RT-qPCR validation

lncRNA MEG3 was selected from the ceRNA network for expression analysis in 12 PRCC tumor tissues and adjacent non-tumor tissues. A total of 12 pairs of paraffin-embedded tissue samples from PRCC patients were collected at the Affiliated Hospital of Southwest Medical University (Luzhou, China) between January 2017 and February 2018. The patients ranged in age from 39 to 80 years, with a median age of 60.5 years, including 8 males and 4 females. All patients were confirmed with primary PRCC by pathological examination of surgical specimens and were not subject to any preoperative radiotherapy or chemotherapy, other malignant disease, or acute injury. The study was approved by the Ethical Review Committee of the Affiliated Hospital of Southwest Medical University. Written informed consent was obtained from all patients prior to sample collection. Total RNA was extracted from PRCC tumor and adjacent normal tissues using a paraffin-embedded tissue RNA extraction kit (Bioteke Corporation, Beijing, China). RT was performed using a ReverTra Ace qPCR RT Master Mix with gDNA Remover (Toyobo Life Science, Tokyo, Japan), according to the manufacturer\'s protocols. Expression level of the lncRNA was detected by qPCR using SYBR Green Realtime PCR Master Mix (Toyobo Life Science) in an Applied Biosystems^™^ 7500 Fast Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA). β-actin served as an internal control. The following primer sequences were used for qPCR: lncRNA MEG3, forward 5′-GCCTGCTGCCCATCTACAC-3′, reverse 5′-CCTCTTCATCCTTTGCCATC-3′; and β-actin, forward 5′-TCCTCTCCCAAGTCCACACA-3′ and reverse 5′-GCACGAAGGCTCATCATTCA-3′. qPCR was conducted as follows: 95°C for 30 sec; 40 cycles of 95°C for 5 sec and 60°C for 30 sec; and a dissociation cycle of 95°C for 15 sec, 60°C for 60 sec, 95°C for 15 sec and 60°C for 15 sec. Each reaction was performed in triplicate, and the relative expression levels (fold change) were calculated using the 2^−ΔΔCq^ method ([@b38-mmr-19-06-4685]). A paired t-test was performed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA) to analyze differences in the expression of lncRNA MEG3 between PRCC tumor tissues and adjacent nontumor tissues (n=12/group). P\<0.05 was considered to indicate a statistically significant difference.

### Survival analysis

To identify prognostic DERNAs for patients with PRCC from TCGA, clinical data were obtained and mapped Kaplan-Meier curves for various DElncRNAs, DEmiRNAs and DEmRNAs were calculated. Patients with PRCC were divided into high expression and low expression groups according to the median value of gene expression. Significant differences in survival between groups were determined using log-rank tests; P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Identification of DEmRNAs, DElncRNAs and DEmiRNAs in PRCC

Transcriptome sequencing data for mRNAs, lncRNAs and miRNAs were analyzed separately using 289 PRCC tumor samples and 32 paracancerous tissue samples. A total of 1,970 DEmRNAs, 1,201 DElncRNAs and 96 DEmiRNAs were identified to have significantly different expression (\|log2-fold change\| ≥2.0 and adjusted P\<0.05) in tumor tissues compared with the adjacent tissue. Volcano plots were generated for the identified DEmRNAs, DElncRNAs and DEmiRNAs ([Fig. 1](#f1-mmr-19-06-4685){ref-type="fig"}). The top 10 upregulated and downregulated DEmRNAs, DElncRNAs and DEmiRNAs are listed in [Table I](#tI-mmr-19-06-4685){ref-type="table"}.

### Analysis of DEmRNAs

Of the 1,970 identified DEmRNAs, 1,092 mRNAs were upregulated and 878 were downregulated. To understand the biological significance of these DEmRNAs, GO and pathway enrichment analyses were conducted. GO analysis provides three categories of information: 'Biological process', 'cellular component' and 'molecular function'. Identified DEmRNAs were primarily enriched in 'metabolic pathways', 'neuroactive ligand-receptor interaction', 'calcium signaling pathways', 'pathways in cancer' and 'cytokine-cytokine receptor interactions'. GO and KEGG pathway analysis results are presented in [Fig. 2](#f2-mmr-19-06-4685){ref-type="fig"}.

A PPI network was constructed to investigate the interactions between the identified DEmRNAs. The PPI network was visualized using Cytoscape ([Fig. 3](#f3-mmr-19-06-4685){ref-type="fig"}). In addition, the top 10 hub DEmRNAs were identified using the CytoHubba plug-in according to degree levels: albumin (ALB), DNA topoisomerase II α (TOP2A), epidermal growth factor (EGF), kininogen 1 (KNG1), leucine rich repeat kinase 2 (LRRK2), baculoviral IAP repeat containing 5 (BIRC5), polo like kinase 1 (PLK1), cyclin A2 (CCNA2), cyclin dependent kinase inhibitor 3 (CDKN3), and aurora kinase B (AURKB); the interaction network is presented in [Fig. 4](#f4-mmr-19-06-4685){ref-type="fig"}.

### Construction and analysis of the lncRNA-miRNA-mRNA ceRNA network

To investigate how lncRNAs and miRNAs cooperate to regulate mRNA expression in PRCC, miRNA-mRNA and lncRNA-miRNA regulatory associations were used to construct an lncRNA-miRNA-mRNA ceRNA network. The differential expression profile consisted of 26 DEmRNA nodes, 65 DElncRNA nodes, 15 DEmiRNA nodes ([Table II](#tII-mmr-19-06-4685){ref-type="table"}) and 287 edges. This reconstructed ceRNA network was visualized using Cytoscape ([Fig. 5](#f5-mmr-19-06-4685){ref-type="fig"}). From the networks, it was determined that DElncRNA MEG3 exhibited potential interactions with 14 DEmiRNAs (hsa-miR-507, hsa-miR-145, hsa-miR-519d, hsa-miR-184, hsa-miR-206, hsa-miR-211, hsa-miR-21, hsa-miR-214, hsa-miR-216a, hsa-miR-216b, hsa-miR-217, hsa-miR-508, hsa-miR-31 and hsa-miR-506). Therefore, it was hypothesized that lncRNA MEG3 may have an important role in regulating the ceRNA network in PRCC. Furthermore, miR-519d interacted with 18 DElncRNAs \[testis-specific transcript Y-linked 14 (TTTY14), AP002478.1, long intergenic non-protein coding RNA (LINC)00221, T cell leukemia/lymphoma 6 (TCL6), LINC00173, AC009061.1, AC061975.6, AC025278.1, MEG3, LINC00269, glutamate metabotropic receptor 7-antisense RNA 3 (GRM7-AS3), LINC00462, zinc finger RANBP2-type containing 2-antisense RNA 1 (ZRANB2-AS1), LINC00330, HOXA distal transcript antisense RNA (HOTTIP), versican-antisense RNA 1 (VCAN-AS1), Pvt1 oncogene (PVT1) and glutamate metabotropic receptor 5-antisense RNA 1 (GRM5-AS1)\] and possessed a targeted regulatory association with eight DEmRNAs \[Rap guanine nucleotide exchange factor 4 (RAPGEF4), E2F transcription factor 2 (E2F2), hyaluronan synthase 2 (HAS2), Sal-like protein 3 (SALL3), ribonucleotide reductase regulatory subunit M2 (RRM2), low density lipoprotein (LDL), DNA polymerase θ (POLQ) and E2F transcription factor 1 (E2F1)\]. The ceRNA subnetwork was extracted using the plug-in MCODE for Cytoscape ([Fig. 6](#f6-mmr-19-06-4685){ref-type="fig"}). This subnetwork consists of hub genes, including lncRNA MEG3, lncRNA Prader-Willi region non-protein coding RNA 1 (PWRN1), hsa-miR-508 and hsa-miR-21, plus certain first neighbors, including neurotrophin 3 (NTF3), tissue inhibitor of metalloproteinase 3 (TIMP3), GRM5-AS1, AP002478.1, TTTY14 and hsa-miR-489.

### RT-qPCR validation

Of the 15 DEmiRNAs that formed the ceRNA network, lncRNA MEG3 exhibited potential interactions with 14 DEmiRNAs, more than any other DElnRNA, suggesting that this lncRNA may be most likely to serve an important role in PRCC. To validate the bioinformatics results, lncRNA MEG3 was selected for expression analysis. LncRNA MEG3 was revealed to be significantly downregulated in PRCC tumor tissue compared with adjacent non-tumor tissues ([Fig. 7](#f7-mmr-19-06-4685){ref-type="fig"}), consistent with the aforementioned bioinformatics analysis.

### Survival analysis using lncRNAs, miRNAs and mRNAs

In the ceRNA network, 13 DEmRNAs were analyzed to determine associations between expression levels and patient survival, including E2F1, E2F2, ETS transcription factor, glypican 5 (GPC5), HAS2, homeobox C13 (HOXC13), interleukin 11 (IL11), LDL receptor (LDLR), POLQ, RAPGEF4, RRM2, selectin E (SELE) and secreted frizzled related protein 1 (SFRP1), all of which were upregulated in patients with PRCC; expression levels of all these genes were associated with overall survival (P\<0.05; [Fig. 8A](#f8-mmr-19-06-4685){ref-type="fig"}). Similarly, the expression of five DElncRNAs \[colorectal neoplasia differentially expressed (CRNDE), GAS6 antisense RNA 1 (GAS6-AS1), GPC5-antisense RNA 1 (GPC5-AS1), LINC00327 and SACS antisense RNA 1 (sacsin-AS1)\] were significantly positively associated with patient survival, whereas 10 \[AP000525.1, glial cell-derived neurotrophic factor-antisense RNA 1 (GDNF-AS1), GLIS family zinc finger 3-antisense RNA 1 (GLIS3-AS1), LINC00221, LINC00310, LINC00462, LINC00473, LRR containing 3-antisense RNA 1 (LRRC3-AS1), surfactant associated 1, pseudogene (SFTA1P) and DNM3 opposite strand (DNM3OS)\] were negatively associated (P\<0.05; [Fig. 8B](#f8-mmr-19-06-4685){ref-type="fig"}). One (hsa-miR-211) and five DEmiRNAs (hsa-miR-145, hsa-miR-184, hsa-mir-214, hsa-miR-216a, hsa-miR-217) were significantly positively and negatively associated with overall survival in PRCC, respectively (P\<0.05; [Fig. 8C](#f8-mmr-19-06-4685){ref-type="fig"}).

Discussion
==========

PRCC accounts for \~18.5% of total cases of RCC ([@b1-mmr-19-06-4685]), and it is generally considered to exhibit an improved prognosis compared with CRCC ([@b3-mmr-19-06-4685]). Therefore, there is a notably reduced level of research into PRCC. Prior to the TCGA report into PRCC ([@b8-mmr-19-06-4685]), no large-scale study systematically investigated the pathogenesis of this disease or aimed to identify prognosis-associated biomarkers. Using TCGA, an in-depth analysis was conducted involving a comprehensive genomics approach to characterize the pathology of 161 cases of PRCC in subtypes 1 and 2 ([@b8-mmr-19-06-4685]); however, due to the heterogeneity of PRCC, the pathogenesis, development and prognosis remain unclear, particularly concerning important ceRNA network-associated mechanisms. PRCC is considered to be highly heterogeneous; however, it was previously reported that \~50% of cases exhibit a certain degree of overlap between type I and type II ([@b3-mmr-19-06-4685]). Therefore, in the present study, sample data for PRCC in TCGA were analyzed to identify factors frequently associated with the pathogenesis, development and prognosis of PRCC.

A large number of samples were obtained from the TCGA database, and gene pathways and hub genes associated with PRCC were identified to determine the mechanisms underlying PRCC incidence. A previous study involving TCGA data mining observed that type 2 tumors were characterized by CDKN2A silencing ([@b8-mmr-19-06-4685]). In the present study, it was reported that CDKN3 was one of 10 hub genes in the ceRNA network. GO and KEGG pathway analyses are frequently used to determine the biological functions of DE coding genes. It was revealed via GO analysis of DEmRNAs that there was significant enrichment of 170 GO 'biological processes' (P\<0.01), including 'excretion', 'epidermis development', 'integral components of plasma membrane', 'extracellular regions', 'calcium ion binding' and 'heparin binding'. The biological functions of the aforementioned DE genes are consistent with the formation and function of renal cells. It has been established that calcium ions affect almost every aspect of cellular life ([@b39-mmr-19-06-4685]), and that variations in cytosolic calcium concentrations induce important cellular events ([@b40-mmr-19-06-4685]). Intracellular calcium overload can initiate mitochondrial-dependent apoptosis ([@b40-mmr-19-06-4685]), which may be a strategy for inhibiting the proliferation of cancer cells ([@b41-mmr-19-06-4685],[@b42-mmr-19-06-4685]). Identified DEmRNAs were also significantly enriched in calcium signaling pathways, as determined by KEGG pathway analysis. Raynal *et al* ([@b43-mmr-19-06-4685]) reported that targeting calcium signaling can reverse the epigenetic silencing of tumor suppressor genes. Additionally, renal cell carcinoma is closely associated with abnormal alterations in metabolic pathways involved in oxygen sensing, energy sensing and nutrient sensing cascades ([@b44-mmr-19-06-4685]--[@b46-mmr-19-06-4685]). A previous study demonstrated that metabolic pathways were altered in metastatic RCC, with downregulation of citric acid cycle genes and upregulation of the pentose phosphate pathway ([@b47-mmr-19-06-4685]). Furthermore, identified DEmRNAs were also enriched in 'pathways in cancer', providing a theoretical basis for further research. Therefore, investigation of these signaling pathways may have notable implications for the identification of biological processes and molecular functions involved in tumorigenesis, progression and metastasis.

The roles of noncoding RNA have been identified following advancements in genetic research, including their central role in the diagnosis, treatment and prognosis of various tumors ([@b48-mmr-19-06-4685]--[@b50-mmr-19-06-4685]). Therefore, a lncRNA-miRNA-mRNA ceRNA network was reconstructed to investigate the roles of noncoding RNAs associated with PRCC via a combination of differential gene expression profile and target analyses. From the ceRNA network, it was hypothesized that lncRNA MEG3 and miR-519d may serve important roles in the regulation of ceRNA networks associated with PRCC. It has been reported that lncRNA MEG3 acts as a lncRNA tumor suppressor in numerous tumors ([@b51-mmr-19-06-4685]--[@b56-mmr-19-06-4685]) via interactions with the tumor suppressor p53 and the regulation of the expression of p53 target genes ([@b57-mmr-19-06-4685]); however, the role of lncRNA MEG3 in PRCC has not yet been investigated.

It was also revealed that miR-519d may occupy an important position in the constructed ceRNA network. Downregulation of miR-519d was reported in studies investigating the molecular mechanisms underlying various tumors, including gastric, ovarian and colorectal cancers ([@b58-mmr-19-06-4685]--[@b60-mmr-19-06-4685]). Additionally, the extraction of a subnetwork identified potentially important RNAs, including lncRNA MEG3, lncRNA PWRN1, hsa-miR-508 and hsa-miR-21. lncRNA PWRN1 has been reported to target miR-425-5p and suppress the development of gastric cancer via p53 signaling ([@b61-mmr-19-06-4685]). miR-508 suppressed the epithelial-mesenchymal transition, migration and invasion of ovarian cancer cells via the mitogen-activated protein kinase 1/ERK signaling pathway ([@b62-mmr-19-06-4685]). Similarly, miR-21 has been reported be involved in numerous molecular mechanisms underlying tumorigenesis ([@b63-mmr-19-06-4685]--[@b65-mmr-19-06-4685]), including ceRNA network regulatory mechanisms ([@b66-mmr-19-06-4685]).

To validate the results of the bioinformatics analyses, lncRNA MEG, a core lncRNA in the ceRNA network, was selected for expression analysis in PRCC tumor tissues and adjacent tissues. RT-qPCR analysis revealed that lncRNA MEG3 was downregulated in tumor tissues compared with adjacent non-tumor tissues. It was recently reported that lncRNA MEG3 expression was decreased in CCRC tissues and cells, affecting the apoptosis, proliferation, migration and invasion of CCRC cells by regulating miR-7/RAS like family 11 member B ([@b67-mmr-19-06-4685]).

Survival analysis revealed that the expression of 13 out of 26 DEmRNAs, 15 out of 65 DElncRNAs and 6 out of 15 DEmiRNAs were significantly associated with survival, indicating that these RNAs may be potential biomarkers for the prognosis of patients with PRCC (P\<0.05). It was observed that the expression of RRM2 was the most significantly associated with survival out of all the RNAs. Wang *et al* ([@b68-mmr-19-06-4685]) reported that low expression of RRM2 was associated with increased time to progression and overall survival in patients with non-small cell lung cancer. Similarly, Zhang *et al* ([@b69-mmr-19-06-4685]) revealed that reduced expression of GPC5 was an independent prognostic marker for the overall survival of patients with prostate cancer. GPC5 protein expression exhibited an association with tumorigenesis and tumor progression in prostate cancer, suggesting a potential application as a novel biomarker for the prediction of diagnosis and prognosis of prostate cancer ([@b70-mmr-19-06-4685]). Furthermore, decreased expression of lncRNA GAS6-AS1 predicted poor prognosis in patients with non-small cell lung cancer ([@b71-mmr-19-06-4685]). These prognosis-associated genes may be potential targets for future clinical treatments, and were identified to be significantly associated with the prognosis of PRCC in the present study.

In conclusion, an lncRNA-miRNA-mRNA ceRNA network was constructed via differential expression and target analyses, demonstrating that lncRNA MEG3 and miR-519d may serve important roles in PRCC. The expression of lncRNA MEG3 was observed to be downregulated in PRCC tumor tissues compared with adjacent non-tumor tissues. The present findings improve understanding of ceRNA network regulatory mechanisms associated with PRCC and may aid future studies into the molecular mechanisms underlying PRCC and the identification of prognostic biomarkers.
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![Volcano plots of DEmRNAs, DElncRNAs and DEmiRNAs in papillary renal cell carcinoma. Red points indicate upregulated genes; green points indicate downregulated genes. DE, differentially expressed; lncRNA, long noncoding RNA; miRNA, microRNA; FC, fold change; FDR, false discovery rate.](MMR-19-06-4685-g00){#f1-mmr-19-06-4685}

![Enriched pathways associated with PRCC. (A) Top 20 GO terms for DEmRNAs associated with PRCC. (B) Top 20 Kyoto Encyclopedia of Genes and Genomes pathways enriched by DEmRNAs associated with PRCC. The color and size of points indicate the significance of the association and the number of genes, respectively. PRCC, papillary renal cell carcinoma; DE, differentially expressed; GO, Gene Ontology; FDR, false discovery rate; GABA, γ-aminobutyric acid; cAMP, cyclic AMP; cGMP, cyclic GMP; PKG, protein kinase G.](MMR-19-06-4685-g01){#f2-mmr-19-06-4685}

![Protein-protein interaction network of papillary renal cell carcinoma-associated DEmRNAs constructed using the Search Tool for the Retrieval of Interacting Genes. Circles indicate protein-coding genes; green indicates downregulated DEmRNAs; red indicates upregulated DEmRNAs. DE, differentially expressed.](MMR-19-06-4685-g02){#f3-mmr-19-06-4685}

![Top 10 hub DEmRNAs extracted from the protein-protein interaction network. Circles indicate protein-coding genes; lines between DEmRNAs indicate direct interactions. DE, differentially expressed; ALB, albumin; TOP2A, DNA topoisomerase II α; KNG1, kininogen 1; LRRK2, leucine-rich repeat kinase 2; CDKN3, cyclin dependent kinase inhibitor 3; EGF, epidermal growth factor; PLK1, polo like kinase 1; BIRC5, baculoviral IAP repeat containing 5; CCNA2, cyclin A2; AURKB, aurora kinase B.](MMR-19-06-4685-g03){#f4-mmr-19-06-4685}

![Reconstruction of lncRNA-miRNA-mRNA network. Diamonds indicate lncRNAs; circles indicate mRNA; rounded rectangles indicate miRNAs; edges indicate interactions. Red indicates upregulation; green indicates downregulation. lncRNA, long noncoding RNA; miRNA/mir, microRNA.](MMR-19-06-4685-g04){#f5-mmr-19-06-4685}

![Subnetwork of the lncRNA-miRNA-mRNA ceRNA network. Diamonds indicate lncRNAs; circles indicate mRNA; round rectangles indicate miRNAs; edges indicate interactions. Red indicates upregulation; green indicates downregulation. lncRNA, long noncoding RNA; miRNA/mir, microRNA; ceRNA, competing endogenous RNA; TIMP3, tissue inhibitor of metalloproteinase 3; GRM5-AS1, glutamate metabotropic receptor 5-antisense RNA 1; NTF, neurotrophin 3; TTTY14, testis-specific transcript Y-linked 14; MEG3, maternally expressed 3; SOX2-OT, SOX2 overlapping transcript; PWRN1, Prader-Willi region non-protein coding RNA 1.](MMR-19-06-4685-g05){#f6-mmr-19-06-4685}

![Expression of lncRNA MEG3 in PRCC tissues. Relative expression of lncRNA MEG3 (normalized to β-actin) in PRCC tumor and adjacent non-tumor control tissue samples. PRCC, papillary renal cell carcinoma; lncRNA MEG3, long noncoding RNA maternally expressed 3.](MMR-19-06-4685-g06){#f7-mmr-19-06-4685}

###### 

Kaplan-Meier survival analysis for papillary renal cell carcinoma-associated RNAs. According to the median value of gene expression, 288 patients with PRCC from The Cancer Genome Atlas were divided into high expression and low expression groups, whose survival data were complete. Survival curves for (A) mRNAs and (B) long noncoding RNAs. Kaplan-Meier survival analysis for papillary renal cell carcinoma-associated RNAs. According to the median value of gene expression, 288 patients with PRCC from The Cancer Genome Atlas were divided into high expression and low expression groups, whose survival data were complete. Survival curves for (C) microRNAs.
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###### 

Top 10 upregulated and downregulated DEmRNAs, DElncRNAs and DEmiRNAs.

  A, Upregulated                                                                                                                    
  ---------------------- -------------- ----------------- ------------ ------------ ----------------- ---------------- ------------ -----------------
  DDB2                   2.1            9.44×10^−53^      AL365181.2   5.8          1.53×10^−40^      hsa-mir-21       2.95         8.32×10^−53^
  BBC3                   2.59           1.22×10^−52^      AC019069.1   3.37         6.25×10^−38^      hsa-mir-561      3.08         1.08×10^−17^
  HK2                    3.56           5.82×10^−44^      AL365181.3   4.61         1.46×10^−35^      hsa-mir-592      3.03         2.78×10^−17^
  LRRC20                 2.07           1.25×10^−43^      AC083862.2   2.15         1.05×10^−31^      hsa-mir-1254-1   2.62         2.02×10^−14^
  GPRIN1                 3.34           1.62×10^−40^      AC005041.3   2.37         1.52×10^−31^      hsa-mir-3934     2.01         9.04×10^−14^
  TMSB10                 2.63           1.97×10^−37^      AC092535.4   4.43         4.79×10^−29^      hsa-mir-4768     2.14         2.40×10^−13^
  TNFSF9                 4.06           3.18×10^−37^      LACTB2-AS1   2.49         1.73×10^−28^      hsa-mir-1293     3.34         4.41×10^−12^
  HAMP                   5.16           2.97×10^−35^      PAQR9-AS1    5.21         2.75×10^−27^      hsa-mir-584      2.29         9.54×10^−12^
  APOC1                  6.5            3.13×10^−34^      GAS6-AS1     3.8          4.41×10^−26^      hsa-mir-7156     4.01         3.23×10^−11^
  TREM2                  4.7            4.32×10^−34^      AL590666.2   3.64         8.35×10^−25^      hsa-mir-4777     2.53         4.57×10^−11^
                                                                                                                                    
  **B, Downregulated**                                                                                                              
                                                                                                                                    
  **DEmRNA**             **DElncRNA**   **DEmiRNA**                                                                                 
                                                                                                                                    
  **Name**               **log2FC**     **FDR P-value**   **Name**     **log2FC**   **FDR P-value**   **Name**         **log2FC**   **FDR P-value**
                                                                                                                                    
  MFSD4A                 −4.72          1.48×10^−274^     AC068631.1   −5.58        1.62×10^−177^     hsa-mir-184      −5.3         4.38×10^−83^
  UMOD                   −12.3          4.41×10^−252^     AC002401.1   −6.42        1.11×10^−173^     hsa-mir-216b     −5.48        2.32×10^−67^
  CALB1                  −8.29          1.71×10^−214^     AC079310.1   −8.36        9.26×10^−153^     hsa-mir-126      −2.15        3.64×10^−48^
  EGF                    −6.21          4.85×10^−206^     AC008264.2   −3.96        8.45×10^−146^     hsa-mir-33a      −2.57        1.37×10^−45^
  GP2                    −8.23          4.61×10^−199^     AC019080.1   −3.69        1.11×10^−138^     hsa-mir-129-2    −3.3         1.45×10^−41^
  GGACT                  −3.57          4.85×10^−191^     AC106772.2   −6.95        5.04×10^−127^     hsa-mir-129-1    −3.2         2.57×10^−39^
  DDN                    −7.01          4.88×10^−187^     AC027309.1   −6.33        1.66×10^−114^     hsa-mir-145      −2.49        4.73×10^−36^
  CRHBP                  −6.08          5.81×10^−186^     AC010442.1   −3.21        6.42×10^−112^     hsa-mir-323a     −2.72        1.45×10^−31^
  PTGER1                 −5.4           1.20×10^−156^     AC099684.2   −4.27        9.72×10^−111^     hsa-mir-206      −3.16        1.70×10^−30^
  SLC26A4                −5.18          3.04×10^−149^     AC105384.1   −5.39        7.77×10^−110^     hsa-mir-489      −3.19        3.16×10^−27^

DE, differentially expressed; lncRNA, long noncoding RNA; miRNA, microRNA; log2FC, log2 fold change; FDR, false discovery rate.

###### 

Key DEmRNAs, DElncRNAs and DEmiRNAs comprising the papillary renal cell carcinoma-associated competing endogenous RNA network.

  RNA type   Name
  ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  DEmRNA     SFRP1, NTF3, GPC5, RAPGEF4, TIMP3, E2F2, LDLR, DACH1, ELE, PRLR, SLC43A1, POLQ, ERG, RRM2, NR4A2, DDC, AHNAK2, IL11, CREB5, HAS2, E2F1, SALL3, TBXA2R, HOXC13, OXGR1, SLC22A6
  DElncRNA   AC021066.1, TMEM72-AS1, ZRANB2-AS1, AC084262.1, TTTY14, KCNC4-AS1, LINC00330, UCA1, C15orf56, SFTA1P, LINC00494, MEG3, AP002478.1, GRM7-AS3, AC012379.1, LINC00269, COL18A1-AS1, AC079341.1, GPC5-AS1, LY86-AS1, LINC00518, PCGEM1, LINC00299, AL359815.1, LINC00221, LINC00310, GLIS3-AS1, LINC00473, TCL6, LINC00355, DLEU7-AS1, F10-AS1, BX255923.1, MIR4500HG, CNTN4-AS1, LINC00327, LINC00173, LRRC3-AS1, AC012640.1, ZFY-AS1, AC009061.1, SACS-AS1, SOX2-OT, LINC00460, AC061975.6, LINC00443, HOTTIP, LINC00462, AC092811.1, ERVMER61-1, ATP1B3-AS1, GAS6-AS1, AC025278.1, DNM3OS, CRNDE, MYCNOS, AP000525.1, MIR205HG, GDNF-AS1, PWRN1, RERG-AS1, AL590369.1, VCAN-AS1, GRM5-AS1, PVT1
  DEmiRNA    hsa-mir-214, hsa-mir-31, hsa-mir-519d, hsa-mir-184, hsa-mir-211, hsa-mir-217, hsa-mir-508, hsa-mir-206, hsa-mir-216b, hsa-mir-506, hsa-mir-216a, hsa-mir-489, hsa-mir-145, hsa-mir-507, hsa-mir-21

DE, differentially expressed; lncRNA, long noncoding RNA; miRNA, microRNA.
